Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              ChemRar

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              RUSSIA Russia

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI Japan 2021

              Participation Not Confirmed

              Update your events

              Clinical Data of Avifavir to Become Available to International Partners

              Contact the Supplier

              Lead Product(s): Favipiravir

              Therapeutic Area: Infections and Infectious Diseases Product Name: Avifavir

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 29, 2020

              Details:

              Russian Direct Investment Fund (RDIF) and the ChemRar Group – will provide international partners with access to special preliminary clinical data for Avifavir, with detailed recommendations for usage of the drug.

              R-Pharm

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              RUSSIA Russia

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI Japan 2021

              Participation Not Confirmed

              Update your events

              Cromos Pharma Supports R-Pharm to Initiate Global Program to Test Two of its Leading Candidates in Patients with Severe COVID-19 Infection

              Contact the Supplier

              Lead Product(s): Olokizumab

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 28, 2020

              Details:

              R-Pharm JSC and Cromos Pharma has randomized the first patients into a clinical trial evaluating Olokizumab and RPH-104 in patients with severe COVID-19 infection.

              PharmaCompass__DigitalAd